Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma

Next Previous
Trial Profile

A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fevipiprant (Primary)
  • Indications Acute asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms LUSTER-2
  • Sponsors Novartis; Novartis Pharma KK; Novartis Pharmaceuticals

Most Recent Events

  • 24 Dec 2019 Topline combined analysis results from the Phase III LUSTER-1 and LUSTER-2 trials presented in a Novartis media release.
  • 16 Dec 2019 According to a Novartis media release, the pivotal replicate LUSTER-1 and LUSTER-2 studies are part of the VIBRANT Phase III program, which also includes the SPIRIT safety study and the supplemental replicate ZEAL-1 and and ZEAL-2 studies.
  • 16 Dec 2019 According to a Novartis media release, detailed efficacy and safety data from the LUSTER-1 and LUSTER-2 studies are being analyzed and will be submitted for presentation at an upcoming medical congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top